Company Performance Metrics
Jayne Gershkowitz: Chief Patient Advocate
Bradley L. Campbell: President & Chief Executive Officer
Amicus Therapeutics is a biotechnology company that focuses on discovering, developing, and commercializing medicines for rare and genetic diseases. It develops and delivers treatment programs, including oral therapies and combination regimens for specific metabolic conditions such as Fabry and Pompe diseases, and it manages research and licensing
activities for additional potential therapies like treatments for focal segmental glomerulosclerosis. The company maintains initiatives that support patient communities affected by rare disorders and collaborates with healthcare and nonprofit organizations to enhance access and advocacy for these disease groups. Amicus also engages in corporate giving programs that support educational, advocacy, and access efforts related to its therapeutic focus areas.
